BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SVACS - ECPv6.15.1.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.siliconvalleyacs.org
X-WR-CALDESC:Events for SVACS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250505T160000
DTEND;TZID=America/Los_Angeles:20250505T170000
DTSTAMP:20260425T093848
CREATED:20250412T152849Z
LAST-MODIFIED:20250417T010437Z
UID:21741-1746460800-1746464400@www.siliconvalleyacs.org
SUMMARY:The Quest for Painstakingly Perfect Painkillers: A Virtual Seminar
DESCRIPTION:Prof. Corey R. Hopkins\, Ph.D.\, University of Nebraska Medical Center\nSponsored by Southern California Section ACS\nMay 5 from 4-5 pm\, Online\, Free\, Registration required\nFunded by the Local Section Activities Committee (LSAC) of the American Chemical Society\n\nABSTRACT \nWork in the Hopkins Laboratory centers around the synthesis and optimization of novel chemical tool compounds aimed at tackling unmet medical needs.  This talk will cover two projects in my lab: 1. Characterization of novel GIRK1/2 activators for the treatment of neuropathic pain\, and 2. The synthesis\, optimization and biological characterization of a series of sigma 1 modulators derived from dopamine 4 antagonists and their use in animal models of pain. \nGIRK1/2 activators are a class of compounds that can modulate G-protein-coupled inwardly rectifying potassium channels\, which are involved in pain signaling pathways. By enhancing GIRK channel activity\, these activators have shown potential in reducing pain perception and providing analgesic effects in preclinical animal models. The work presented herein outlines the ongoing structure-activity relationship (SAR) studies centered around a potent\, efficacious\, and selective positive allosteric modulators (PAM) of the GIRK1/2 channel. Sigma 1 antagonists have gained attention for their potential to modulate pain by blocking the sigma-1 receptor\, which is involved in various cellular processes\, including pain transmission. Preclinical studies suggest that these antagonists may reduce nociceptive signaling\, offering a novel approach to pain management. In the second part\, I’ll describe our efforts at the identification of novel dopamine 4 receptor antagonists and how that effort morphed into the discovery of potent and selective sigma 1 modulators. \nBIOGRAPHY \nDr. Hopkins is a Professor and Interim Chair in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Nebraska Medical Center and the Director of the newly designated UNMC Center for Drug Design and Innovation (CDDI). Corey completed his doctorate in 2002 at the University of Pittsburgh in the area of natural product total synthesis and he developed a novel ring expansion methodology to make pharmacophore analogs of dnacin. Dr. Hopkins moved to Aventis Pharmaceuticals in 2001 and later became Senior Research Investigator in Medicinal Chemistry. In 2008\, Dr. Hopkins served as Associate Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery where he led the chemistry efforts on multiple projects that led to pharmaceutical partnerships and a first-in-class clinical candidates. He is the author of more than 110 peer reviewed articles and an inventor on >25 patents. In addition\, he has been named to Stanford/Elsevier’s Top 2% scientist rankings for the past 8 years. \nDr. Hopkins has expertise in medicinal chemistry and drug discovery. Dr. Hopkins’ laboratory focuses on the development of chemical probes to elucidate the mechanisms in therapeutic areas such as pain\, Parkinson’s disease and cancer.
URL:https://www.siliconvalleyacs.org/event/the-quest-for-painstakingly-perfect-painkillers-a-virtual-seminar/
LOCATION:Virtual
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.siliconvalleyacs.org/wp-content/uploads/2025/04/Southern-CA-Section-ACS-scaled-e1744471816100.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250510T103000
DTEND;TZID=America/Los_Angeles:20250510T120000
DTSTAMP:20260425T093848
CREATED:20250508T160957Z
LAST-MODIFIED:20250508T160957Z
UID:21774-1746873000-1746878400@www.siliconvalleyacs.org
SUMMARY:From the Laboratory to the Marketplace: The Development of a New Drug
DESCRIPTION:Natalie McClure\, Senior Regulatory Affairs and Product Development Consultant\nSponsored by California Section ACS\, Women Chemists Committee\n10:30 am-Noon\, Online\, Free\, May 10\, 2025. Registration required by May 8th at Noon\nDownload the flyer for this event\n\nAbstract\nDrug development requires a delicate balance between innovation\, efficacy\, safety\, and regulatory compliance. This talk will explore the multifaceted process of bringing a new drug from the laboratory to the market\, focusing on the critical role of regulatory affairs in ensuring patient safety and product quality. We will examine the key stages of drug development\, including pre-clinical studies\, clinical trials\, and risk-benefit analysis. We will also discuss how to interpret the package insert. We will discuss how drug developers can work with the FDA to bring the new drug to the market. \nSpeaker Bio\nNatalie McClure is a regulatory affairs consultant with extensive experience in drug development\, regulatory affairs and quality assurance. She obtained a BS in Chemistry from the University of Michigan in 1974 followed by a PhD in Organic Chemistry from Stanford University in 1979. She started her career at Syntex Research\, working in the process development laboratories on new synthetic approaches to prostaglandin and large-scale peptide synthesis and then changed career direction to drug regulatory affairs. \nOver the past 40 years\, she has worked at several different companies\, big and small\, as an individual contributor and executive\, and helped get over 6 drugs approved for marketing. She has filed more than 50 INDs (Investigational New Drugs)\, orphan drug applications and conducted many pre-IND meetings with the FDA. Natalie is an instructor at St Mary’s University and the UC Berkeley Extension program offering several courses in drug development and regulatory affairs. Natalie is also very active in the American Chemical Society serving as chair and councilor of the Silicon Valley local section.
URL:https://www.siliconvalleyacs.org/event/from-the-laboratory-to-the-marketplace-the-development-of-a-new-drug/
LOCATION:Virtual
CATEGORIES:Morning Meeting,Webinar
ATTACH;FMTTYPE=image/png:https://www.siliconvalleyacs.org/wp-content/uploads/2021/02/McClure_Natalie.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250514T170000
DTEND;TZID=America/Los_Angeles:20250514T190000
DTSTAMP:20260425T093848
CREATED:20250406T212553Z
LAST-MODIFIED:20250510T223623Z
UID:21684-1747242000-1747249200@www.siliconvalleyacs.org
SUMMARY:Polymers for Capacitors\, Transistors\, and Fun
DESCRIPTION:Dr. Yi Liu\, Molecular Foundry\, Lawrence Berkeley Lab\n5:00-7:00 pm\, Free\, Hybrid: In-person at Stanford Chemistry Department or virtual\, Registration required. \nAbstract\nPolymers with engineered functionalities play a crucial role in electronics and energy applications. Advancing materials discovery in this space requires tailored molecular design and innovative polymer architectures. My recent research focuses on designing molecular and macromolecular systems that either inhibit or facilitate charge transport—key factors in defining a polymer’s insulating or semiconducting properties. In this talk\, I will discuss dielectric polymers designed for capacitors operating under extreme electric fields and temperatures\, highlighting strategies to enhance their breakdown strength and capacitive energy storage performance. In contrast\, for applications such as field-effect transistors\, where efficient charge transport is critical\, I will present new classes of low-bandgap conjugated polymers enabled by a versatile quinoidal unit. Beyond their electronic applications\, the unique reactivity of the quinoidal unit allows for the formation of single-crystalline polymers\, opening new avenues in polymer science. Through these examples\, I will showcase how molecular design can be leveraged to expand the functionality and versatility of polymers. \nShort Bio\nYi Liu is a Senior Staff Scientist and director of the Organic Facility at the Molecular Foundry\, Lawrence Berkeley National Laboratory\, USA. He earned his Ph.D. in Chemistry in 2004 from the University of California\, Los Angeles. After his postdoctoral research at the Scripps Research Institute\, he joined the Molecular Foundry in 2006 as a staff scientist\, launching his independent research career. His research interests include design and self-assembly of functional organic and organic-inorganic hybrid framework materials\, materials chemistry for organic electronics\, and fundamental understanding of the associated electronic processes. \n 
URL:https://www.siliconvalleyacs.org/event/polymers-for-capacitors-transistors-and-fun/
LOCATION:In-person at Stanford Chemistry Department & Hybrid
CATEGORIES:Webinar,Lecture
ATTACH;FMTTYPE=application/pdf:https://www.siliconvalleyacs.org/wp-content/uploads/2025/04/FlyerSVACS-GGPF_JointSeminar_Liu-MolecularFoundry_14May2025-1.pdf
END:VEVENT
END:VCALENDAR